Glutamyl-cysteine

By Targets:	Akt (5) AMPK (5) Apoptosis (5) Biochemical Assay Reagents (1) Endogenous Metabolite (7) Ferroptosis (12) Interleukin Related (5) JAK (5) JNK (5) NF-κB (5) p38 MAPK (5) PI3K (5) Reference Standards (5) Sirtuin (5) STAT (5) TNF Receptor (5)
By Research Areas:	Cancer (7) Cardiovascular Disease (4) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (4)

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-106376

DL-Buthionine-(S,R)-sulfoximine Maximum Cited Publications 35 Publications Verification Buthionine sulfoximine; BSO	Ferroptosis	Cancer
DL-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.

HY-106376A

L-Buthionine-(S,R)-sulfoximine 15+ Cited Publications L-Buthionine sulfoximine; L-BSO	Ferroptosis	Cancer
L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of *g-glutamylcysteine* synthetase and depletes cellular glutathione levels. The IC₅₀** value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.

HY-113402

Gamma-glutamylcysteine 4 Publications Verification γ-Glu-Cys	Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-113402A

*Gamma-glutamylcysteine* TFA** 4 Publications Verification γ-Glu-Cys TFA	Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-106376B

DL-Buthionine-(S,R)-sulfoximine hydrochloride Maximum Cited Publications 35 Publications Verification Buthionine sulfoximine hydrochloride; BSO hydrochloride	Ferroptosis	Cancer
DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.

HY-106376C

L-Buthionine-(S,R)-sulfoximine hydrochloride 15+ Cited Publications L-Buthionine sulfoximine hydrochloride; L-BSO hydrochloride	Ferroptosis	Metabolic Disease Cancer
L-Buthionine-(S,R)-sulfoximine hydrochloride is a cell-permeable, potent, fast acting, orally active and irreversible inhibitor of *g-glutamylcysteine* synthetase and depletes cellular glutathione levels. The IC₅₀** value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively .

HY-159703

Glu-Cys Glutamyl-cysteine; PSSGlu-Cys	Endogenous Metabolite	Others
Glu-Cys (Glutamyl-cysteine; PSSGlu-Cys) is a dipeptide composed of L-glutamic acid (HY-14608) and L-cysteine (HY-Y0337) joined by a peptide linkage .

HY-113402R

*Gamma-glutamylcysteine* (Standard)** γ-Glu-Cys (Standard)	Reference Standards Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis	Inflammation/Immunology
Gamma-glutamylcysteine (Standard) is the analytical standard of Gamma-glutamylcysteine. This product is intended for research and analytical applications. Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

HY-113402AR

*Gamma-glutamylcysteine* TFA (Standard)** γ-Glu-Cys TFA (Standard)	Interleukin Related TNF Receptor Endogenous Metabolite Reference Standards AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Gamma-glutamylcysteine (TFA) (Standard) is the analytical standard of Gamma-glutamylcysteine (TFA). This product is intended for research and analytical applications. Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

HY-113402B

*Gamma-glutamylcysteine* ammonium** γ-Glu-Cys ammonium	Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Gamma-glutamylcysteine ammonium (γ-Glu-Cys ammonium) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine ammonium activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine ammonium regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* ammonium is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-E70614

Glutathione Synthetase, Human	Endogenous Metabolite	Others
Glutathione Synthetase, Human catalyzes the production of glutathione from gamma-glutamylcysteine and glycine in an ATP-dependent manner .

HY-106376R

DL-Buthionine-(S,R)-sulfoximine (Standard) Buthionine sulfoximine (Standard); BSO (Standard)	Reference Standards Ferroptosis	Cancer
DL-Buthionine-(S,R)-sulfoximine (Standard) is the analytical standard of DL-Buthionine-(S,R)-sulfoximine. This product is intended for research and analytical applications. DL-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.

HY-106376BR

DL-Buthionine-(S,R)-sulfoximine hydrochloride (Standard) Buthionine sulfoximine hydrochloride (Standard); BSO hydrochloride (Standard)	Reference Standards Ferroptosis	Cancer
DL-Buthionine-(S,R)-sulfoximine (hydrochloride) (Standard) is the analytical standard of DL-Buthionine-(S,R)-sulfoximine (hydrochloride). This product is intended for research and analytical applications. DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.

HY-CE01792

*Gamma-glutamylcysteine-CoA* Gamma-Glutamylcysteine-coenzyme A	Biochemical Assay Reagents	Metabolic Disease
Gamma-glutamylcysteine-CoA (Gamma-glutamylcysteine-coenzyme A) is a coenzyme A derivative .

HY-106376AR

L-Buthionine-(S,R)-sulfoximine (Standard) L-Buthionine sulfoximine (Standard); L-BSO (Standard)	Reference Standards Ferroptosis	Cancer
L-Buthionine-(S,R)-sulfoximine (Standard) is the analytical standard of L-Buthionine-(S,R)-sulfoximine (HY-106376A). This product is intended for research and analytical applications. L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC₅₀ value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.

Art. -Nr.	Produktname	Target	Research Area

HY-159703

Glu-Cys Glutamyl-cysteine; PSSGlu-Cys	Endogenous Metabolite	Others
Glu-Cys (Glutamyl-cysteine; PSSGlu-Cys) is a dipeptide composed of L-glutamic acid (HY-14608) and L-cysteine (HY-Y0337) joined by a peptide linkage .

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-113402

Gamma-glutamylcysteine 4 Publications Verification γ-Glu-Cys	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-113402A

*Gamma-glutamylcysteine* TFA** 4 Publications Verification γ-Glu-Cys TFA	Structural Classification Natürliche Produkte Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease .

HY-113402R

*Gamma-glutamylcysteine* (Standard)** γ-Glu-Cys (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (Standard) is the analytical standard of Gamma-glutamylcysteine. This product is intended for research and analytical applications. Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

HY-113402AR

*Gamma-glutamylcysteine* TFA (Standard)** γ-Glu-Cys TFA (Standard)	Structural Classification Natürliche Produkte Endogenous metabolite Source Classification	Interleukin Related TNF Receptor Endogenous Metabolite Reference Standards AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis
Gamma-glutamylcysteine (TFA) (Standard) is the analytical standard of Gamma-glutamylcysteine (TFA). This product is intended for research and analytical applications. Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and *GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine* TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.

Art. -Nr.	Compare	Produktname	Species	Source	Image

HY-P71511

	Gamma-GCS Protein, E.coli (His-SUMO) gshA; gsh-I; b2688; JW2663Glutamate--cysteine ligase; EC 6.3.2.2; Gamma-ECS; GCS; Gamma-Glutamylcysteine synthetase	E.coli	E. coli
	Gamma-GCS protein is a key enzyme in sulfur metabolism and initiates glutathione synthesis by catalyzing the incorporation of L-cysteine and L-glutamic acid. This important molecule critical for cellular antioxidant defense is synthesized through a critical 1/2 step facilitated by γ-GCS. Gamma-GCS Protein, E.coli (His-SUMO) is the recombinant E. coli-derived Gamma-GCS protein, expressed by E. coli , with N-His, N-SUMO labeled tag.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

Host:	Rabbit (5)
Reactivity:	Human (5) Rat (5) Mouse (5)
Application:	IHC-P (2) ICC/IF (3) IP (3) WB (5) FC (1) ELISA (2)
Isotype:	IgG (5)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Unmodified (4)

Art. -Nr.	Compare	Produktname	Application	Reactivity	Image

HY-P83153

	GCLC Antibody (YA2898) GCLC; GLCL; GLCLC; Glutamate--cysteine ligase catalytic subunit; GCS heavy chain; Gamma-ECS; Gamma-Glutamylcysteine synthetase	WB	Human, Mouse, Rat
	GCLC Antibody (YA2898) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GCLC.

HY-P86305

	GCLC Antibody (YA5997) GCLC; GLCL; GLCLC; Glutamate--cysteine ligase catalytic subunit; GCS heavy chain; Gamma-ECS; Gamma-Glutamylcysteine synthetase	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	GCLC Antibody (YA5997) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GCLC.

HY-P83153A

	GCLC Antibody (YA2898)(PBS only) GCLC; GLCL; GLCLC; Glutamate--cysteine ligase catalytic subunit; GCS heavy chain; Gamma-ECS; Gamma-Glutamylcysteine synthetase	WB	Human, Mouse, Rat
	GCLC Antibody (YA2898) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GCLC.

HY-P81662

	GCLM Antibody (YA1407) GCLM; GLCLR; Glutamate--cysteine ligase regulatory subunit; GCS light chain; Gamma-ECS regulatory subunit; Gamma-Glutamylcysteine synthetase regulatory subunit; Glutamate--cysteine ligase modifier subunit	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	GCLM Antibody (YA1407) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GCLM.

HY-P86557

	GCLM Antibody (YA6249) GCLM; GLCLR; Glutamate--cysteine ligase regulatory subunit; GCS light chain; Gamma-ECS regulatory subunit; Gamma-Glutamylcysteine synthetase regulatory subunit; Glutamate--cysteine ligase modifier subunit	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	GCLM Antibody (YA6249) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GCLM.

Compare Products


Products	Auf Lager - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / Auf Lager - + In den Warenkorb hinzufügen Angebot einholen

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.

Glutamyl-cysteine

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products